Get the Stockscreener App
1.53
2.55%
-0.04
Pre-market:
1.53
Perspective Therapeutics Inc stock is currently priced at $1.53, with a 24-hour trading volume of 10.69M.
It has seen a -2.55% decreased in the last 24 hours and a +4.79% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.60 pivot point. If it approaches the $1.29 support level, significant changes may occur.
Previous Close:
$1.57
Open:
$1.57
24h Volume:
10.69M
Market Cap:
$897.98M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-18.75
EPS:
-0.0816
Net Cash Flow:
$-37.99M
1W Performance:
-15.00%
1M Performance:
+4.79%
6M Performance:
+491.19%
1Y Performance:
+0.00%
1D Range:
$1.44
$1.60
52W Range:
$0.205
$1.905
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Defense World
GT Medical Technologies acquires cancer treatment subsidiary from Seattle company - The Business Journals
The Business Journals
Perspective Therapeutics (NYSEAMERICAN:CATX) Sees Large Volume Increase - MarketBeat
MarketBeat
Insider Buying: Lantheus Alpha Therapy, LLC, Perspective Therapeutics Inc [CATX] 10% Owner invested 60431039 ... - Knox Daily
Knox Daily
Inhibikase Therapeutics Inc Inc. (IKT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
The InvestChronicle
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Significant Increase in Short Interest - MarketBeat
MarketBeat
Perspective Therapeutics Inc Stock (CATX) Financials Data
Perspective Therapeutics Inc (CATX) Revenue 2024
CATX reported a revenue (TTM) of $6.96 million for the quarter ending September 30, 2023, a -35.56% decline year-over-year.
Perspective Therapeutics Inc (CATX) Net Income 2024
CATX net income (TTM) was -$46.51 million for the quarter ending December 31, 2023, a -411.25% decrease year-over-year.
Perspective Therapeutics Inc (CATX) Cash Flow 2024
CATX recorded a free cash flow (TTM) of -$37.98 million for the quarter ending December 31, 2023, a -393.89% decrease year-over-year.
Perspective Therapeutics Inc (CATX) Earnings per Share 2024
CATX earnings per share (TTM) was -$0.1716 for the quarter ending December 31, 2023, a -186.00% decline year-over-year.
About Perspective Therapeutics Inc
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
2.41%
0.21%
Cap:
|
Volume (24h):